PLGA from PolySciTech used in development of bone-targeting nanoparticles for treatment of MRSA

 

Bacterial infection of bone tissue is extremely difficult to treat due to poor drug delivery. Researchers at Temple University (Philadelphia) used PLGA (Cat# AP022, https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP022#h) ) from PolySciTech : Akina, Inc. (www.PolySciTech.com) to develop bone-targeting nanoparticles for treatment of bone-MRSA. This research holds promise to provide treatment for this disease. Read more: Guo, Pengbo, Bettina A. Buttaro, Hui Yi Xue, Ngoc T. Tran, and Ho Lun Wong. "Bone-targeting lipid-polymer hybrid nanoparticles for less invasive, injectable local antibiotic treatment of bone infections by methicillin-resistant Staphylococcus aureus (MRSA)." International Journal of Pharmaceutics (2025): 126539. https://www.sciencedirect.com/science/article/pii/S0378517325013766

“Effective treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus (MRSA) requires sufficiently high antibiotic concentrations at the infected bone sites. Local drug therapy such as antibiotic-impregnated beads or cement is a valuable option but requires invasive surgical procedures for implantation and sometimes removal. In this study, lipid-polymer hybrid nanoparticles decorated with alendronate, known as bone-targeting nanoparticles (BTN), were tailored for local antibiotic treatment of MRSA-osteomyelitis in a bone-targeting fashion. BTN loading linezolid demonstrated size around 100 nm in diameter that remained stable in serum- or calcium- supplemented medium, encapsulation efficiency around 60 % and controlled drug release properties, and were shown to be significantly more effective than free linezolid against MRSA both in their biofilm and intracellular forms. Significant bone-targeting affinity was demonstrated in hydroxyapatite screening (5.5-fold enhancement over no-alendronate nanoparticles) and ex vivo porcine bone model. BTN injected into animal legs resulted in lasting local bone-accumulation of nanoparticles with minimal distribution to most remote organs, leading to up to 34.9-fold antibiotic level enhancement at the injected bone legs over free drug group. In animal osteomyelitis model, BTN groups achieved multiple log10 scale reduction (p < 0.01) in bacteria CFU counts post-treatment with less blood platelet count reduction (p < 0.05) when compared with free drug group. Overall, this study highlights the excellent potential of a more active, less invasive nanodelivery-based approach for targeting those poorly accessible MRSA pathogens of osteomyelitis.”

Benchtop to Bedside with MidWest GMP https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/